The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Analysis of Plasma Epstein–Barr Virus DNA to Screen for Nasopharyngeal Cancer
Abstract
BACKGROUND: Circulating cell-free Epstein-Barr virus (EBV) DNA is a biomarker for nasopharyngeal carcinoma. We conducted a prospective study to investigate whether EBV DNA in plasma samples would be useful to screen for early nasopharyngeal carcinoma in asymptomatic persons. METHODS: We analyzed EBV DNA in plasma specimens to screen participants who did not have symptoms of nasopharyngeal carcinoma. Participants with initially positive results were retested approximately 4 weeks later, and those with persistently positive EBV DNA in plasma underwent nasal endoscopic examination and magnetic resonance imaging (MRI). RESULTS: A total of 20,174 participants underwent screening. EBV DNA was detectable in plasma samples obtained from 1112 participants (5.5%), and 309 (1.5% of all participants and 27.8% of those who initially tested positive) had persistently positive results on the repeated sample. Among these 309 participants, 300 underwent endoscopic examination, and 275 underwent both endoscopic examination and MRI; of these participants, 34 had nasopharyngeal carcinoma. A significantly higher proportion of participants with nasopharyngeal carcinoma that was identified by screening had stage I or II disease than in a historical cohort (71% vs. 20%, P<0.001 by the chi-square test) and had superior 3-year progression-free survival (97% vs. 70%; hazard ratio, 0.10; 95% confidence interval, 0.05 to 0.18). Nine participants declined to undergo further testing, and 1 of them presented with advanced nasopharyngeal carcinoma 32 months after enrollment. Nasopharyngeal carcinoma developed in only 1 participant with negative EBV DNA in plasma samples within 1 year after testing. The sensitivity and specificity of EBV DNA in plasma samples in screening for nasopharyngeal carcinoma were 97.1% and 98.6%, respectively. CONCLUSIONS: Analysis of EBV DNA in plasma samples was useful in screening for early asymptomatic nasopharyngeal carcinoma. Nasopharyngeal carcinoma was detected significantly earlier and outcomes were better in participants who were identified by screening than in those in a historical cohort. (Funded by the Kadoorie Charitable Foundation and the Research Grants Council of the Hong Kong government; ClinicalTrials.gov number, NCT02063399 .).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
Bettegowda, C., Sausen, M., Leary, R. J., Kinde, I., Wang, Y., Agrawal, N., Bartlett, B. R., Wang, H., Luber, B., Alani, R. M., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3007094 · Cited by 5,067
Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer
Mok, T. S., Wu, Y.-L., Ahn, M.-J., Garassino, M. C., Kim, H. R., Ramalingam, S. S., Shepherd, F. A., He, Y., Akamatsu, H., Theelen, W. S. M. E., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1612674 · Cited by 3,379
Analysis of Circulating Tumor DNA to Monitor Metastatic Breast Cancer
Dawson, S.-J., Tsui, D. W. Y., Murtaza, M., Biggs, H., Rueda, O. M., Chin, S.-F., Dunning, M. J., Gale, D., Forshew, T., Mahler-Araujo, B., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1213261 · Cited by 2,207
Tie, J., Wang, Y., Tomasetti, C., Li, L., Springer, S., Kinde, I., Silliman, N., Tacey, M., Wong, H.-L., Christie, M., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aaf6219 · Cited by 1,492
(15031584), Y. M. D. L., Chan, L. Y. S., Lo, K. W., Leung, S. F., Zhang, J., Chan, A. T. �., Lee, J. C., Hjelm, N. M., Johnson, P. J., & Huang, D. P. (1999) · PubMed · Cited by 777
Self-citationLeary, R. J., Sausen, M., Kinde, I., Papadopoulos, N., Carpten, J. D., Craig, D., O’Shaughnessy, J., Kinzler, K. W., Parmigiani, G., Vogelstein, B., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3004742 · Cited by 635
Treatment results for nasopharyngeal carcinoma in the modern era: The Hong Kong experience
Lee, A. W. M., Sze, W. M., Au, J. S. K., Leung, S. F., Leung, T. W., Chua, D. T. T., Zee, B. C. Y., Law, S. C. K., Teo, P. M. L., Tung, S. Y., et al. (2005) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2004.07.702 · Cited by 587
Self-citationDetection of aberrant p16 methylation in the plasma and serum of liver cancer patients.
Wong, I. H. N., Lo, Y. M. D., Zhang, J., Liew, C.-T., Ng, M. H. L., Wong, N., Lai, P. B. S., Lau, W. Y., Hjelm, N. M., & Johnson, P. J. (1999) · PubMed · Cited by 517
Self-citationChan, K. A., Jiang, P., Zheng, Y. W., Liao, G. J., Sun, H., Wong, J., Siu, S. S. N., Chan, W. C., Chan, S. L., Chan, A. T., et al. (2013) · Clinical Chemistry · doi:10.1373/clinchem.2012.196014 · Cited by 488
Self-citationChan, A. T. �., Lo, Y. M. D., Zee, B., Chan, L. Y. S., Ma, B. B. Y., Leung, S.-F., Mo, F., Lai, M., Ho, S., Huang, D. P., et al. (2002) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/94.21.1614 · Cited by 452
Self-citation
Cited by
Head and neck squamous cell carcinoma
Johnson, D. E., Burtness, B., Leemans, C. R., Lui, V. W. Y., Bauman, J. E., & Grandis, J. R. (2020) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-00224-3 · Cited by 4,067
Chen, Y.-P., Chan, A. T. C., Le, Q.-T., Blanchard, P., Sun, Y., & Ma, J. (2019) · The Lancet · doi:10.1016/s0140-6736(19)30956-0 · Cited by 3,077
Self-citationA view on drug resistance in cancer
Vasan, N., Baselga, J., & Hyman, D. M. (2019) · Nature · doi:10.1038/s41586-019-1730-1 · Cited by 2,770
Current and future perspectives of liquid biopsies in genomics-driven oncology
Heitzer, E., Haque, I. S., Roberts, C. E. S., & Speicher, M. R. (2019) · Nature Reviews Genetics · doi:10.1038/s41576-018-0071-5 · Cited by 1,557
Merker, J. D., Oxnard, G. R., Compton, C., Diehn, M., Hurley, P., Lazar, A. J., Lindeman, N., Lockwood, C. M., Rai, A. J., Schilsky, R. L., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.76.8671 · Cited by 959
Application of Cell-free DNA Analysis to Cancer Treatment
Corcoran, R. B., & Chabner, B. A. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1706174 · Cited by 950
Epigenetics, fragmentomics, and topology of cell-free DNA in liquid biopsies
Lo, Y. M. D., Han, D. S. C., Jiang, P., & Chiu, R. W. K. (2021) · Science · doi:10.1126/science.aaw3616 · Cited by 662
Self-citationFeasibility of blood testing combined with PET-CT to screen for cancer and guide intervention
Lennon, A. M., Buchanan, A. H., Kinde, I., Warren, A., Honushefsky, A., Cohain, A. T., Ledbetter, D. H., Sanfilippo, F., Sheridan, K., Rosica, D., et al. (2020) · Science · doi:10.1126/science.abb9601 · Cited by 657
Circulating tumor DNA and liquid biopsy in oncology
Cescon, D. W., Bratman, S. V., Chan, S. M., & Siu, L. L. (2020) · Nature Cancer · doi:10.1038/s43018-020-0043-5 · Cited by 600
Self-citationThe emerging role of cell-free DNA as a molecular marker for cancer management
Bronkhorst, A. J., Ungerer, V., & Holdenrieder, S. (2019) · Biomolecular Detection and Quantification · doi:10.1016/j.bdq.2019.100087 · Cited by 566
Nasopharyngeal carcinoma: an evolving paradigm
Wong, K. C. W., Hui, E. P., Lo, K.-W., Lam, W. K. J., Johnson, D., Li, L., Tao, Q., Chan, K. C. A., To, K.-F., King, A. D., et al. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00524-x · Cited by 546
Self-citationUnravelling tumour heterogeneity by single-cell profiling of circulating tumour cells
Keller, L., & Pantel, K. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0180-2 · Cited by 544
Farrell, P. J. (2019) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathmechdis-012418-013023 · Cited by 541
The future of early cancer detection
Fitzgerald, R. C., Antoniou, A. C., Fruk, L., & Rosenfeld, N. (2022) · Nature Medicine · doi:10.1038/s41591-022-01746-x · Cited by 457
Bossi, P., Chan, A. T., Licitra, L., Trama, A., Orlandi, E., Hui, E. P., Halámková, J., Mattheis, S., Baujat, B., Hardillo, J., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2020.12.007 · Cited by 447
Self-citationAccess to pathology and laboratory medicine services: a crucial gap
Wilson, M. L., Fleming, K. A., Kuti, M. A., Looi, L. M., Lago, N., & Ru, K. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30458-6 · Cited by 444
Tang, L., Chen, Y., Chen, C., Chen, M., Chen, N., Chen, X., Du, X., Fang, W., Feng, M., Gao, J., et al. (2021) · Cancer Communications · doi:10.1002/cac2.12218 · Cited by 413
Clinical relevance of blood-based ctDNA analysis: mutation detection and beyond
Keller, L., Belloum, Y., Wikman, H., & Pantel, K. (2021) · British Journal of Cancer · doi:10.1038/s41416-020-01047-5 · Cited by 401
The Evolving Epidemiology of Nasopharyngeal Carcinoma
Chang, E. T., Ye, W., Zeng, Y.-X., & Adami, H.-O. (2021) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-20-1702 · Cited by 387
Investigation of Long COVID Prevalence and Its Relationship to Epstein-Barr Virus Reactivation
Gold, J. E., Okyay, R. A., Licht, W. E., & Hurley, D. J. (2021) · Pathogens · doi:10.3390/pathogens10060763 · Cited by 371
Circulating biomarkers in the diagnosis and management of hepatocellular carcinoma
Johnson, P., Zhou, Q., Dao, D. Y., & Lo, Y. M. D. (2022) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-022-00620-y · Cited by 320
Self-citationSong, P., Wu, L. R., Yan, Y. H., Zhang, J. X., Chu, T., Kwong, L. N., Patel, A. A., & Zhang, D. Y. (2022) · Nature Biomedical Engineering · doi:10.1038/s41551-021-00837-3 · Cited by 319
Best, M. G., Wesseling, P., & Wurdinger, T. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-0887 · Cited by 297
The Biology of Cell-free DNA Fragmentation and the Roles of DNASE1, DNASE1L3, and DFFB
Han, D. S. C., Ni, M., Chan, R. W. Y., Chan, V. W. H., Lui, K. O., Chiu, R. W. K., & Lo, Y. M. D. (2020) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2020.01.008 · Cited by 259
Self-citationGenomic Medicine–Progress, Pitfalls, and Promise
Shendure, J., Findlay, G. M., & Snyder, M. W. (2019) · Cell · doi:10.1016/j.cell.2019.02.003 · Cited by 254
Detection of Solid Tumor Molecular Residual Disease (MRD) Using Circulating Tumor DNA (ctDNA)
Chin, R.-I., Chen, K., Usmani, A., Chua, C., Harris, P. K., Binkley, M. S., Azad, T. D., Dudley, J. C., & Chaudhuri, A. A. (2019) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-019-00390-5 · Cited by 191
Metadata
- Authors
- Chan, K. C. A., Woo, J. K. S., King, A., Zee, B. C. Y., Lam, W. K. J., Chan, S. L., Chu, S. W. I., Mak, C., Tse, I. O. L., Leung, S. Y. M., Chan, G., Hui, E. P., Ma, B. B. Y., Chiu, R. W. K., Leung, S.-F., van Hasselt, A. C., Chan, A. T. C., & Lo, Y. M. D.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2017-08-10
- Volume
- 377
- Issue
- 6
- Pages
- 513-522
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2742681205
- Cited by
- 781
- References
- 22
- FWCI
- 27.47
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.